224 related articles for article (PubMed ID: 18642854)
1. Characterization of the peptidoglycan of vancomycin-susceptible Enterococcus faecium.
Patti GJ; Kim SJ; Schaefer J
Biochemistry; 2008 Aug; 47(32):8378-85. PubMed ID: 18642854
[TBL] [Abstract][Full Text] [Related]
2. Characterization of structural variations in the peptidoglycan of vancomycin-susceptible Enterococcus faecium: understanding glycopeptide-antibiotic binding sites using mass spectrometry.
Patti GJ; Chen J; Schaefer J; Gross ML
J Am Soc Mass Spectrom; 2008 Oct; 19(10):1467-75. PubMed ID: 18692403
[TBL] [Abstract][Full Text] [Related]
3. Effect of Vancomycin on Cytoplasmic Peptidoglycan Intermediates and
Gargvanshi S; Vemula H; Gutheil WG
J Bacteriol; 2021 Jul; 203(16):e0023021. PubMed ID: 34060906
[TBL] [Abstract][Full Text] [Related]
4. Vancomycin and oritavancin have different modes of action in Enterococcus faecium.
Patti GJ; Kim SJ; Yu TY; Dietrich E; Tanaka KS; Parr TR; Far AR; Schaefer J
J Mol Biol; 2009 Oct; 392(5):1178-91. PubMed ID: 19576226
[TBL] [Abstract][Full Text] [Related]
5. Quantification of the d-Ala-d-Lac-Terminated Peptidoglycan Structure in Vancomycin-Resistant Enterococcus faecalis Using a Combined Solid-State Nuclear Magnetic Resonance and Mass Spectrometry Analysis.
Chang JD; Foster EE; Yang H; Kim SJ
Biochemistry; 2017 Jan; 56(4):612-622. PubMed ID: 28040891
[TBL] [Abstract][Full Text] [Related]
6. Structures of Staphylococcus aureus cell-wall complexes with vancomycin, eremomycin, and chloroeremomycin derivatives by 13C{19F} and 15N{19F} rotational-echo double resonance.
Kim SJ; Cegelski L; Preobrazhenskaya M; Schaefer J
Biochemistry; 2006 Apr; 45(16):5235-50. PubMed ID: 16618112
[TBL] [Abstract][Full Text] [Related]
7. Substrate Inhibition of VanA by d-Alanine Reduces Vancomycin Resistance in a VanX-Dependent Manner.
van der Aart LT; Lemmens N; van Wamel WJ; van Wezel GP
Antimicrob Agents Chemother; 2016 Aug; 60(8):4930-9. PubMed ID: 27270282
[TBL] [Abstract][Full Text] [Related]
8. Peptidoglycan structure of Enterococcus faecium expressing vancomycin resistance of the VanB type.
Billot-Klein D; Shlaes D; Bryant D; Bell D; van Heijenoort J; Gutmann L
Biochem J; 1996 Feb; 313 ( Pt 3)(Pt 3):711-5. PubMed ID: 8611145
[TBL] [Abstract][Full Text] [Related]
9. Fluorescence assay to predict activity of the glycopeptide antibiotics.
Vimberg V; Gazak R; Szűcs Z; Borbás A; Herczegh P; Cavanagh JP; Zieglerova L; Závora J; Adámková V; Balikova Novotna G
J Antibiot (Tokyo); 2019 Feb; 72(2):114-117. PubMed ID: 30504918
[TBL] [Abstract][Full Text] [Related]
10. Activation of the L,D-transpeptidation peptidoglycan cross-linking pathway by a metallo-D,D-carboxypeptidase in Enterococcus faecium.
Sacco E; Hugonnet JE; Josseaume N; Cremniter J; Dubost L; Marie A; Patin D; Blanot D; Rice LB; Mainardi JL; Arthur M
Mol Microbiol; 2010 Feb; 75(4):874-85. PubMed ID: 20025663
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Staphylococcus aureus Cell Wall Biosynthesis by Desleucyl-Oritavancin: a Quantitative Peptidoglycan Composition Analysis by Mass Spectrometry.
Chang JD; Foster EE; Thadani AN; Ramirez AJ; Kim SJ
J Bacteriol; 2017 Aug; 199(15):. PubMed ID: 28507244
[TBL] [Abstract][Full Text] [Related]
12. Hidden Mode of Action of Glycopeptide Antibiotics: Inhibition of Wall Teichoic Acid Biosynthesis.
Singh M; Chang J; Coffman L; Kim SJ
J Phys Chem B; 2017 Apr; 121(16):3925-3932. PubMed ID: 28368603
[TBL] [Abstract][Full Text] [Related]
13. Modified peptidoglycan precursors produced by glycopeptide-resistant enterococci.
Messer J; Reynolds PE
FEMS Microbiol Lett; 1992 Jul; 73(1-2):195-200. PubMed ID: 1521770
[TBL] [Abstract][Full Text] [Related]
14. Vancomycin derivative with damaged D-Ala-D-Ala binding cleft binds to cross-linked peptidoglycan in the cell wall of Staphylococcus aureus.
Kim SJ; Matsuoka S; Patti GJ; Schaefer J
Biochemistry; 2008 Mar; 47(12):3822-31. PubMed ID: 18302341
[TBL] [Abstract][Full Text] [Related]
15. The Carboxyl Terminus of Eremomycin Facilitates Binding to the Non-d-Ala-d-Ala Segment of the Peptidoglycan Pentapeptide Stem.
Chang J; Zhou H; Preobrazhenskaya M; Tao P; Kim SJ
Biochemistry; 2016 Jun; 55(24):3383-91. PubMed ID: 27243469
[TBL] [Abstract][Full Text] [Related]
16. Desleucyl-Oritavancin with a Damaged d-Ala-d-Ala Binding Site Inhibits the Transpeptidation Step of Cell-Wall Biosynthesis in Whole Cells of Staphylococcus aureus.
Kim SJ; Singh M; Sharif S; Schaefer J
Biochemistry; 2017 Mar; 56(10):1529-1535. PubMed ID: 28221772
[TBL] [Abstract][Full Text] [Related]
17. Conformational and quantitative characterization of oritavancin-peptidoglycan complexes in whole cells of Staphylococcus aureus by in vivo 13C and 15N labeling.
Cegelski L; Steuber D; Mehta AK; Kulp DW; Axelsen PH; Schaefer J
J Mol Biol; 2006 Apr; 357(4):1253-62. PubMed ID: 16483598
[TBL] [Abstract][Full Text] [Related]
18. Quantitative analysis of the metabolism of soluble cytoplasmic peptidoglycan precursors of glycopeptide-resistant enterococci.
Arthur M; Depardieu F; Reynolds P; Courvalin P
Mol Microbiol; 1996 Jul; 21(1):33-44. PubMed ID: 8843432
[TBL] [Abstract][Full Text] [Related]
19. Peptidoglycan composition of vancomycin-resistant Enterococcus faecium.
de Jonge BL; Gage D; Handwerger S
Microb Drug Resist; 1996; 2(2):225-9. PubMed ID: 9158764
[TBL] [Abstract][Full Text] [Related]
20. Oritavancin exhibits dual mode of action to inhibit cell-wall biosynthesis in Staphylococcus aureus.
Kim SJ; Cegelski L; Stueber D; Singh M; Dietrich E; Tanaka KS; Parr TR; Far AR; Schaefer J
J Mol Biol; 2008 Mar; 377(1):281-93. PubMed ID: 18258256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
